Akero Therapeutics Inc expected to post a loss of 63 cents a share - Earnings Preview

Akero Therapeutics

31/07/2023 13:47

* Akero Therapeutics Inc  AKRO.OQ   AKRO.O  is expected
to show no
change in quarterly revenue when it reports  results on August 2
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Akero Therapeutics
Inc is
for a loss of 63 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akero
Therapeutics Inc is $60​, above​ its last closing price
of $42.46. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.66       -0.67      -0.55     Beat    18.2
 Dec. 31 2023  -0.81       -0.80      -0.49     Beat    38.6
 Sep. 30 2022  -0.71       -0.74      -0.92     Missed  -24.7​
 Jun. 30 2022  -0.79       -0.86      -0.77     Beat    10
 ​​Mar.        -0.82       -0.80      -0.74     Beat    7.3
 31 2022                                                
 Dec. 31 2021  -0.83       -0.82      -0.93     Missed  -13.6​
 Sep. 30 2021  -0.91       -0.91      -0.70     Beat    23.1
 Jun. 30 2021  -0.65       -0.72      -0.83     Missed  -14.7
 This summary was machine generated July 31 at 12:47 GMT.  All
figures in US dollars  unless otherwise stated